Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 1/20 | 0.60 |
| ▸ | CA1 | P00915 | 11/20 | 0.54 |
| ▸ | CA2 | P00918 | 11/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 9/20 | 0.49 |
| ▸ | CA12 | O43570 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.47 |
| ▸ | ACR | P10323 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4214461 | 0.96 | PLG (0.56) | PLGCA1CA2KMT2AMEN1 | |
| SCHEMBL10956570 | 0.89 | KMT2A (0.56) | KMT2AMEN1ALDH1A1PRSS1ACR | |
| SCHEMBL11314000 | 0.86 | ACR (0.47) | PLGKMT2AMEN1ALDH1A1PRSS1 | |
| SCHEMBL7615600 | 0.85 | STAT3 (0.51) | PLGCA1CA2KMT2AMEN1 | |
| SCHEMBL11308024 | 0.85 | MAPT (0.62) | KMT2AMEN1ALDH1A1PRSS1ACR | |
| SCHEMBL11316711 | 0.84 | PARP10 (0.61) | PLGCA1CA2KMT2AMEN1 | |
| SCHEMBL11304744 | 0.84 | ACR (0.47) | PLGKMT2AMEN1ALDH1A1PRSS1 | |
| SCHEMBL7328271 | 0.83 | ACR (0.58) | CA1CA2KMT2AMEN1ALDH1A1 | |
| SCHEMBL11569991 | 0.83 | KMT2A (0.54) | KMT2AMEN1ALDH1A1PRSS1ACR | |
| SCHEMBL11310818 | 0.83 | SMN1; SMN2 (0.47) | PLGKMT2AMEN1ALDH1A1PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0287036-B1 | NEW PHARMACEUTICAL COMPOSITIONS COMPRISING ESTERS OR AMIDES AS ACTIVE INGREDIENTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 1991-04-10 | — | — | EP | claimed |
| EP-0287036-A2 | New pharmaceutical compositions comprising esters or amides as active ingredients | ONO PHARMACEUTICAL CO., LTD. (JP) | 1988-10-19 | — | — | EP | claimed |
| US-4283418-A | ANTIPLASMIN AND ANTITRYPSIN AGENTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 1981-08-11 | — | — | US | claimed |
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | THE SCRIPPS RESEARCH INSTITUTE | 2023-11-02 | — | — | US | disclosed |
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | THE SCRIPPS RESEARCH INSTITUTE | 2023-11-02 | — | — | US | disclosed |
| WO-2021225767-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-11-11 | — | — | WO | disclosed |
| US-5110602-A | Solution or suspension in middle chain glyceride to inhibit degradation by digestive enzymes | ONO PHARMACEUTICAL CO., LTD. (JP) | 1992-05-05 | — | — | US | disclosed |
| EP-0287036-B1 | NEW PHARMACEUTICAL COMPOSITIONS COMPRISING ESTERS OR AMIDES AS ACTIVE INGREDIENTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 1991-04-10 | — | — | EP | disclosed |
| US-5004612-A | Dissolved in a middle chain glyceride of a fatty acid | ONO PHARMACEUTICAL CO., LTD. (JP) | 1991-04-02 | — | — | US | disclosed |
| US-4889723-A | SUSPENDED OR DISSOLVED IN GLYCERIDE; STABILITY | ONO PHARMACEUTICAL CO., LTD. (JP) | 1989-12-26 | — | — | US | disclosed |
| EP-0287036-A2 | New pharmaceutical compositions comprising esters or amides as active ingredients | ONO PHARMACEUTICAL CO., LTD. (JP) | 1988-10-19 | — | — | EP | disclosed |
| US-4283418-A | ANTIPLASMIN AND ANTITRYPSIN AGENTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 1981-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | ACE2, SARS1, ACE | PLG 185/4885CA1 3538/4885CA2 1779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.